41 % of newly diagnosed breast cancer patients were included in the JBCS registry in 2005. In this prognostic study, we analyzed 9971 cases in which the survival data were available from 161 facilities. The background characteristics of the patients are summarized in Table 1 . The median follow-up period was 60.0 months (range 0.1-60.0 months). Note that during the study period, not only the cutoff levels of estrogen receptor and progesterone receptor but also their corresponding test procedures were non-standardized and that trastuzumab was rarely used because it was not covered by the Japanese National Health Insurance program as an adjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. On the whole, the survival data seem to be better than expected. However, it would be prudent to avoid commenting on any specific subject because the present study is part of an annual survival report. A data set spanning multiple years would be more suitable for addressing specific subjects, such as triple-negative type or HER2 type. This is planned for the next phase studies. Fig. 1 a, Cancer control activities vary among nations and regional areas due to differences in population structures. The life expectancy for Japanese women, 87 years old in 2012, has been the longest worldwide for several years [6] . In addition, Japan is a super-aging society, with 25 % of citizens being 65 years of age or above as of October 2013, which is the highest number among all other nations [7] . We believe that the outcomes of our registry provide significant information for countries that are expected to have a similar population structure to that of Japan in the near future. Fig. 2 a, b Kaplan-Meier curves for relapse-free and overall survival of all cases by regional lymph nodes status (cN-category). N0: no regional lymph node metastases; N1: metastases in movable ipsilateral level I, II axillary lymph node(s); N2: metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted OR metastases in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases; N3: metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involvement OR metastases in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases OR metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. P values were calculated using the log rank test Tumor size is a marker of invasiveness. P values were calculated using the log rank test P values were calculated using the log rank test. Relapse-free survival and overall survival of patients with respect to combined ER and HER2 status Fig. 8 a, b Kaplan-Meier curves for relapse-free and overall survival of ER-positive and M0 cases by progesterone receptor (PgR) status. P values were calculated using the log rank test Breast Cancer (2016) 23:50-61 59 Fig. 9 a, b Kaplan-Meier curves for relapse-free and overall survival of ER-positive and M0 cases with respect to PgR and HER2 amplifications. P values were calculated using the log rank test
